SPEAKERS
Mien-Chie Hung
AFFILIATION:
China Medical University, Taichung, Taiwan Academia Sinica, Taiwan,
POSITION TITLE:
President and Academician
EDUCATION/TRAINING:
National Taiwan University, Taiwan B.S. 1973 Chemistry
National Taiwan University, Taiwan M.S. 1977 Biochemistry
Brandeis University, MA, USA Ph.D. 1983 Biochemistry
Whitehead Institute, MIT, MA Postdoc 1986 Oncogene (Mentor: RA Weinberg)
HONORS:
John P. McGovern Award for Outstanding Teaching, U.T. H.S.C. -Houston (1990, 1993, 1999, 2018),
Faculty Achievement Award in Education (1993) and in Basic Research (1998, 2017), UTMDACC
Member, Pathology B Study Section (1996 – 2000) and Sub-committee C (2001-2005), NIH.
Founding Editorial Board, Cancer Cell 2001; Editor-in-Chief, American Journal for Cancer Research 2015-
2002 Academician of the Academia Sinica, Taiwan, ROC
2006 Member, The University of Texas Academy of Health Science Education
2007 Distinguished Teaching Professor, UT MD Anderson Cancer Center
2010-16 Full Member, Scientific Advisory Council, Susan G Komen
2010 Fellow, section of Biological Sciences, American Association for the Advancement of Science
2014-18 Overseas Member, Scientific Advisory Board*, Institute of Molecular and Cellular Biology, A*STAR, Singapore,
2017 Regents’ Outstanding Teaching Award, The University of Texas System
2018-19 President-elect, The University of Texas Kenneth I Shine, MD Academy of Health Science Education
2013- present Member, Review and Selection Committee in the Biopharmaceutical Science Category, Tang Prize
2017-20 Chair, Search committee of director of Institute of Molecular Biology, Academia Sinica(中央研究院)
2019-2021 臺灣綠色大學聯盟第4屆理事
2020 台灣生物產業發展協會 第十六屆理事
2020 第 16 屆永信李天德醫藥科技獎評審委員
2020 第24屆教育部國家講座主持人生物及醫農科學類評審委員
2020-2021 總統科學獎委員會委員
2020 教育部「玉山學者」計畫【醫學】領域審議委員
2020-2022 Member, Academic Advisory Board (AAC), Institute of Molecular Biology
2021 國家衛生研究院分子與基因醫學研究所(分基所)學術評鑑委員
RESEARCH INTERESTS:
Dr. Hung was a Principal Investigator for 2 R01s, 1 CPRIT, T32 and U01 grants right before retiring from M D Anderson in Feb. 2019. Currently, Dr. Hung maintains active research programs both in China Medical University at Taiwan and in MD Anderson Cancer Center, where he served as a vice president of basic research and the chair of the department of Molecular and Cellular Oncology. Dr. Hung’s research group focuses on the following areas: 1) Unravel non-canonical signal pathways of Epidermal Growth Factor Receptor (EGFR); 2) Identification of crosstalk signaling pathways in cancer cells to predict resistance for targeted therapy; 3) Elucidation of posttranslational modifications that play critical roles in tumor progression; 4) Discovery of signaling pathways and key regulators that are specific and critical to cancer stem cells proliferation; 5) Development of effectively immunotherapy and study of resistant mechanisms of immunotherapy.
PUBLICATIONS:
List of published work in Google Scholar:
https://scholar.google.com/citations?hl=zh-TW&user=IZYtdLgAAAAJ